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The highly conserved transmembrane sequences ofsurface Igs(sIgs) suggest that
thesemoleculesmay associate with other integral membrane proteins to executetheir
dual functionsofligand bindingand signal transduction (1, 2). Tcellstudies suggest
that such lineage-specific functions are mostlikely mediated by lineage-specific an-
tigens (3-5). Whilefouradditional B cell-specificsurfaceantigens havebeen identified
(CD19, CD20, CD22, and CD72) (6-9), their functions are unknown.
Since sIg is one of N30% of B cell surface antigens that modulate, we used a
comodulation assay to search for sIg-associated B cell antigens. Antibody-induced
antigenic modulation is the rapid, specific, and reversible loss of surface antigens
caused by incubating cells at 370C with an excess of specific antibody (10). Occa-
sionally, chemically distinct antigens comodulate, indicatingthat theyare physically
associated. For example, anti-CD3 mAbs comodulate the TCR (Ti) (3, 5). Simi-
larly, modulation ofCD3Ti by antigen or specific antibody comodulatesCD4/CD8
(11, 12); confirming the close physical and functional association between CD3Ti
and CD4/CD8 (4). Our studies indicate that the B cell-specific and pan-B sIg and
CD19 surface antigens are functionally and physically associated.
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Cells.
￿
Cells were cultured in RPMI 1640 medium (Gibco Laboratories, Grand Island,
NY) supplemented with 10% FCS (HyClone Laboratories, Logan, UT). B cells from tonsils
ofpatients at Children's Hospital Medical Center, Seattle, WA, were harvested using stan-
dard methods.
mAbs.
￿
HB43 (1410KG7), HB57 (DA4-4), and HB45 (141PF11) mAbs specific for Ig y,
A, and K chains were obtained from theAmerican Type Culture Collection (Bethesda, MD).
Except for fluoresceinated CD19-specific B4 mAb (6) (Coulter Immunology, Hialeah, FL)
andCD22-specific G28-7 mAb(Dr.Jeffrey Ledbetter, Oncogen, Seattle, WA), all mAbs were
prepared in our own laboratory unless indicated.
mAbs werepurified usingproteinA-Sepharosecolumns (Sigma Chemical Co., St. Louis,
MO),tested bySDS-PAGE, andfluoresceinated using standardmethods. Molar fluorescein
protein ratios ranged from 6 to 10. Antibody bindingwas determined using either directly
fluoresceinated mAbsorbyusingfluoresceinatedgoatanti-mouseantibody(TagoInc.,Burlin-
game, CA) in indirect immunofluorescence assays monitored on the FACS (Becton Dick-
inson& Co.; Mountain View, CA), withfluorescencedisplayedinlogarithmic mode. All proce-
dureswere performed using an excess ofmAbs with 0.1% NaN3 at 4°C to preventantigenic
modulation.
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Modulation.
￿
Cells (106/ml) are incubated under standard tissue culture conditions with
10 Wg/ml of purified mAb for the times indicated (usually 20 h) (10). Identical cultures are
incubated with isotype-matched mAbs to sIg, CD19, or CD4 antigens. Changes in binding
ofdirectly fluoresceinated mAbs are expressed by dividing the mean channel of fluorescence
observed on reactive antibody-treated cells (anti-Ig or anti-CD19) by that observed with con-
trol (anti-CD4)-treated cells after correcting for nonspecific binding.
Cocapping.
￿
Cells are incubated with directly fluoresceinated mAbs to test antigens and
with Texas red-conjugated polyclonal anti-human X chain-specific antiserum (G/HIgTR)
(Tago Inc.) or unlabeled y chain-specific mAb (HB43) for 70 min at 37°C, washed, and
analyzed using a laserscanning confocal microscope (MRC-500; Bio-Rad Laboratories, Cam-
bridge, MA) with a Nikon Optiphot (Nikon, Torrance, CA). G/HIg-TR does not crossreact
with mouse Ig.
Results
Incubation of B cells with an excess of Ig-specific mAbs at 37°C causes rapid,
virtually complete loss ofsIg (13). Modulation with anti-Ig mAb also selectively reduces
binding of fluoresceinated mAbs specific for CD19 (Fig. 1). Binding ofJ3-119 mAb
is reduced on average to 35% of its original value on SKLY18, 34 1 /o on Ramos, and
43% on BALM-3 cells. F(ab)'2 fragments of anti-Ig mAbs also comodulate CD19.
The process is reversible, since modulated cells incubated without anti-Ig mAbs for
48 h show normal levels of sIg and CD19.
The extracellular region of CD19 contains three Ig-like domains (14). Since sIg
and CD19 modulate with anti-Ig and anti-CD19 mAb, respectively (13, 15), comodu-
lation of CD19 by anti-Ig antibodies could reflect serologic crossreactivity between
sIg and CD19, but it does not. Comodulation of CD19 is observed when sIgG on
SKLY18 cells is modulated by y or A chain-specific mAb, when sIgG on BALM-3
cells is modulated by y or « chain-specific mAb, and when sIgM on Ramos cells
is modulated by p, or a chain-specific mAb. It is improbablethat antibodies specific
for sIg y, p,, tc, and X chains all crossreact with CD19. Modulation of sIgM on Ramos
cells by an idiotype-specific mAb (JS-10) also comodulates CD19.
Modulation using anti-Ig rnAb reduces binding of 15 CD19-specific mAbs. 10 mAbs
were obtained from the Fourth International Leukocyte Workshop, Vienna (B-C3,
CLB-CD19, B43, B-G4, B-Ly3, HD37, HD237, B4, ABI, and BU-12). Five mAbs
were prepared in our laboratory (J3-129, J3-144, and J4-166), including two (J4-35
and J3-119) from the workshop. Modulation of CD19 byJ3-119 reduces binding of
FIGURE 1.
￿
Incubation ofBcells with anti-Ig mAb comodulates CD19.
B cell lines Ramos (A, k), SKLY18 (y, a), and BALM-3 (,y, K) are
studied in A, B, and C, respectively. Cells are incubated with the ap-
propriate purified anti-Ig mAb (10 hg/ml) or with an isotype-matched
negative control mAb (anti-CD4) at 37°C. At 20 h, indirect im-
munofluorescence assay indicates loss of >95% of sIg from anti-Ig-
treated cells. Directly fluoresceinated mAbs measure CD19 on con-
trol and anti-Ig-treated samples (solidanddashed thicklines, respectively).
Binding offluoresceinated nonreactive anti-CD4 mAb to both samples
is indicated by overlapping sets of dotted lines.100
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FIGURE 2. (a)ComodulationofCD19by
anti-IgmAbs is concentration dependent.
SKLY18 cells are incubatedfor20 hwith
increasing dilutions (log3-") of either X
chain-specific (J6-17) or CD4-specific
mAbs (J5-20), beginning at a purified
mAbconcentration of 10 hg/ml. Directly
fluoresceinated mAbs measureexpression
X CD19
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is plotted. Maximumefficiency ofsIgmod-
ulation as measured usinganti--y mAb is
only 90% in this experiment. (b) Anti-Ig
mAbs induce concurrent changes in ex-
pression of sIg and CD19. SKLY18 cells
areincubatedwith .y chain-specific mAb
HB43 at 37°C. Expression ofsIgG a chain
(J6-17), CD19 (J3-119), andCD45 (J-33)
is measured at indicated times using
directly fluoresceinatedmAbs andmoni-
tored on the FAGS. Identical results for
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Time (min)
lation hasno effect on expression ofCD45.
the other 14 CD19-specific mAbs. These 15 mAbs detect at least three CD19 epi-
topes, as determined by binding to lymphocytes ofbaboon and macaque and com-
petitive inhibition studies with B4-FITC.
Modulation of sIg by anti-Ig mAb comodulates CD19 on nine of nine mature
B cell lines and on normal tonsil B cells. Incubation with mAbs specific for both
CD19 and sIg enhances the rate and extent of CD19 modulation. When 18 surface
antigens are studied on nine anti-Ig-treated mature Bcell linesusingdirectly fluorescei-
nated mAbs (HLA I, HLA II, CD9, CD10, CD19, CD20, CD22, CD45, CD45R,
CD46, CD48, CD71, p23, p35,90, p60, p124, p129, and p160,200), only expression
of CD19 is consistently and significantly reduced.
Comodulation of CD19 and sIg is unidirectional. Modulation of CD19 by anti-
CD19 mAb on nine ofnine cell lineshasno effect on expression of sIgor otherantigens.
Higher concentrations of anti-Ig mAb increase the comodulation of CD19 (Fig.
2 a). sIgG (HB43) and CD19 (J3-119) aremeasured on SKLY18 cells incubated with
increasing dilutions (1093-X) of X chain-specific mAb (J6-17) or isotype-matched
CD4-specific mAb (J5-20). Changes in expression of sIg and CD19 also occur con-
currently with time during anti-Ig modulation, suggesting that these are parallel
rather than serial events. In Fig. 2 b, 87 and 95% ofsIgG, and 22 and 29% of CD19
are lost from SKLY18 cells during anti-Ig modulation at 40 and 360 min, respec-
tively. Expression of CD45 is not affected.
Anti-Ig mAb (HB43) induces capping of fluoresceinated mAb specific for CD19
but not otherantigens (CD20[B1], CD45 [J-33], andCD46 [J-48]). Anti-CD19 mAbs
alone do not cap under these conditions. Two-color studies using fluoresceinated2162
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FIGURE 3.
￿
Anti-Ig and anti-CD19 antibodies cocap. SKLY18 cells are incubated with Texas
red-conjugated goat anti-humanXchain-specific antibody and with fluoresceinated anti-CD19
mAb (J3-119) for 70 min at 37°C. The same field is analyzed for fluorescein (left) andTexas red
(right) stain . Field depth is 1 ;Lm . The two sets of caps overlap, and most appear to be within
cells . Some anti-CD19 mAb remains on the cell surface .
anti-CD19 mAb (J3-129, J3-144, orJ3-119) and Texas red-conjugated anti-Ig anti-
body show that anti-Ig and anti-CD19 cocap (Fig. 3), but anti-CD45 (J-33), anti-la
(J-70), anti-p35,90 (JS-56), and anti-p23 (JS-64) do not . Not all of each anti-CD19
mAb caps, consistent with the comodulation data . Labeled anti-CD19 and anti-Ig
antibodies appear within capped cells, suggesting that they are internalized .
Discussion
Anti-IgmAbs cause rapid, specific, concentration-dependent, and reversible uni-
directional comodulation of the CD19 phosphoglycoprotein on all mature B cells
studied . Anti-Ig mAbs cause specific cocapping and apparent internalization of sIg
and CD19, indicating both physical and functional interactions between these two
B cell-specific and pan-B surface molecules, or between CD19and some other mole-
cule associated with sIg . Previously (16), anti-CD19 mAbs were shown to inhibit
the rapid calcium ion changes and cellular proliferation caused by antibodies to sIg.
Comodulation of CD19 by anti-Ig mAbs is not due to serologic crossreactivity
between CD19 and sIg ; mAbs specific for the y, it, a, and X chains of sIg and at
least one idiotype-specific mAb all produce this effect . Comodulation of CD19 is
observed on all mature B cells studied, indicating that it is not a unique feature of
one or two cell lines . Binding of 15 of 15 CD19-specific mAbs that identify at leastPESANDO ET AL.
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three different determinants on CD19 is reduced under these conditions, indicating
that the effect is not due to an idiosyncratic property of a single anti-CD19 mAb.
Of 18 antigens studied, CD19 is the only one comodulated by anti-Ig mAb. The
parallel loss of sIg and CD19 caused by anti-Ig mAb with time and with varying
antibody concentration, and thecocappingdata, suggest that these are simultaneous
rather than serial events.
The observation that sIg and CD19 comodulate with anti-Ig but not anti-CD19
mAb was unexpected. One explanation is that sIg and CD19 associate only in the
presence of antigen or antigen substitutes. Such ligands would induce a change in
sIg, possibly conformational, enabling it to bind CD19. Independent expression of
sIg and CD19 is also indicated by the presence of CD19 on sIg' pre-B cells, large
excess of sIg over CD19 on many B cells, and ability of 10 ug/ml of anti-Ig mAb
to produce virtually complete modulation of sIg but not CD19.
These studies demonstrateboth functional and physical interactions between sIg
and CD19. The long cytoplasmic tail of CD19 (148 amino acids) (14) relative to sIg
(four amino acids for sIgM) (1, 2) suggests that CD19 could facilitate signal trans-
duction when antigen is bound to sIg.
Summary
Thepan-B and B cell-specific sIg and CD19 antigens are functionally and physi-
cally associated in the presence of anti-Ig mAb. Incubation of B cells with anti-Ig
antibodies causes rapid, specific, reversible, concentration-dependent, and unidirec-
tional comodulation ofCD19 on everymature B cell studied. Comodulation is pro-
duced by mAbs specific forthe-y, R, u, and Xchains ofIg, andby at least oneidiotype-
specific mAb. Comodulation is observed using 15 C1319-specific mAbs that detect
at least three different CD19 epitopes. Of 18 surface antigens studied, only CD19
is comodulated. Loss of sIg and CD19 occurs concurrently during anti-Ig modula-
tion anddemonstrates acomparable dependence on anti-Igconcentration, suggesting
that these are parallel rather than serial events. Incubation with anti-Ig specifically
cocaps and suggests internalization of anti-CD19 mAb. Comodulation of sIg and
CD19 by anti-Ig but not anti-CD19 mAbs suggests that ligand binding enables sIg
to then interact with CD19. We propose that CD19 is a component of the B cell an-
tigen recc.otor and suggest that it could facilitate signal transduction by sIg-antigen
complext ,.
We thank Dr. Sen-itiroh Hakomori for his valuable support and counsel throughout these
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